Cardiol Therapeutics Inc. (CRDL)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. David G. Elsley MBA | President, CEO & Director | 539.22k | -- | -- |
| Mr. Christopher J. Waddick C.A., C.M.A., CPA, CMA, MBA | CFO, Corporate Secretary & Director | 212.49k | -- | -- |
| Mr. Bernard Lim B.Sc. | Chief Operating Officer | 371.86k | -- | -- |
| Dr. Andrew Warwick Hamer M.D. | Chief Medical Officer and Head of Research & Development | 538.12k | -- | 1962 |
| Trevor Burns | Investor Relations | -- | -- | -- |
| Mr. John A. Geddes BSCPT, MBA | Vice President of Corporate Development | -- | -- | -- |
Cardiol Therapeutics Inc.
- Sector:
- Healthcare
- Industry: Drug Manufacturers - Specialty & Generic
- Full Time Employees:
- 18
Description
Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the developing of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product candidate is CardiolRx, which is in Phase III multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis. The company is also developing CRD-38 injection for subcutaneous administration that is in preclinical development for the treatment of heart failure. It has a license agreement with Meros. The company was incorporated in 2017 and is headquartered in Oakville, Canada.
Corporate Governance
Upcoming Events
April 29, 2025 at 8:00 PM UTC - May 9, 2025 at 8:00 PM UTC
Cardiol Therapeutics Inc. Earnings Date